Seminiar 30-11-2013 Side effects treat opo short

50 %
50 %
Information about Seminiar 30-11-2013 Side effects treat opo short
Health & Medicine

Published on March 6, 2014

Author: stichtingiwo

Source: slideshare.net

Description

Side effects treat opo short

n e Nevenwerkingen van medicaties bij fractuurpreventie: klinisch relevant? . r h . P s u e G Prof Piet Geusens, MD, PhD Reumatoloog Maastricht UMC & UHasselt

n e Disclosure belangen spreker (potentiële) belangenverstrengeling s u e G Voor bijeenkomst mogelijk relevante relaties met bedrijven   Honorarium of andere (financiële) vergoeding Aandeelhouder Andere relatie, namelijk … . r h   . P Sponsoring of onderzoeksgeld Geen Geen  Pfizer, Abbott, Lilly, Amgen, MSD, Will, Roche  Pfizer, Abbott, Lilly, Amgen, MSD, UCB, Will, BMS, Novartis  Geen  NVT

Nevenwerkingen in RCTs . r h . P s u e G n e

n e . r h . P CALCIUM s u e G

Bolland 2008 . P n e s u e G Boland 2010 Calcium treatment was associated with: • increased risk of myocardial infarction dietary calcium intake > 805 mg/day (HR 1.85, 1.28-2.67) • no increased risk in those with dietary calcium intake < 805mg/day (HR 0.98, 0.691.38) . r h BMJ 2008;336;262-266; BMJ 2010;341:c3691

n e s u e G Participants 61 433 women (born between 1914 and 1948) followed-up for a median of 19 years (Michaelson, BMJ, 2013) . r h . P

n e . r h . P s u e G RCT 1200 mg calcium vs placebo; women ≥ 70. Base-line dietary intake 950 mg calcium JBMR, Vol. 25, 2010, pp 2205–2211

n e Adjusted dose-response association between daily calcium supplement intake and risk for cardiovascular death . r h . P s u e G Plos One 2013: e61037

Medische behandeling: calcium en vitamine D s u e G – Optimalisatie van calcium inname: • Totaal: 1000-1200 mg calcium/dag – Vb: geen melkproducten . P – Vb: 1-2 zuivelporties/dag – Vb: 3-4 zuivelporties/dag . r h MUMC&UHasselt n e + 3-4 zuivelporties of 1000 mg calcium supplement + 1-2 zuivelporties of +500 mg calcium supplement geen aanpassing nodig 1 zuivelportie = 1 stevig glas melk 1 pot yoghurt 1 schel kaas

n e . r h . P VITAMIN D s u e G

Vitamin D supplements s u e G n e • Toxic dose: >10.000 IU/d • Annual oral 500,000 IU of cholecalciferol – 26% increased risk of fracture and a 15% increased risk of falling compared to placebo (Sanders, JAMA, 2010) . P • Oral cholecalciferol 150,000 IU/3-monthly – neither beneficial nor adverse effects on falls or physical function (Glendennig, JBMR, 2012) . r h

Vitamin D supplements in patients with a recent fracture . r h . P n e s u e G Before CBO 2011 Loading dose according to baseline 25(OH)D 80% achieved >50 nmol/L After CBO 2011 Fixed dose of 800IU/d 80% achieved >50 nmol/L Shab-Bidar, European Journal of Endocrinology (2013) 169 597

n e . r h . P s u e G A vitamin D3 dosage of 800 IU/d increased serum 25-(OH)D levels to greater than 50 nmol/L in 97.5% of women Gallagher, AIM, 2012

Medische behandeling: calcium en vitamine D s u e G – Optimalisatie van calcium inname: • Totaal: 1000-1200 mg calcium/dag – Vb: geen melkproducten – Vb: 1-2 zuivelporties/dag . P – Vb: 3-4 zuivelporties/dag – Vitamine D: 800 E/dag • • • • n e + 3-4 zuivelporties of 1000 mg calcium supplement + 1-2 zuivelporties of +500 mg calcium supplement geen aanpassing nodig Bij osteoporose behandeling Bij mensen in verzorgingsinstelling Hoger indien nodig Na recente fractuur . r h MUMC&UHasselt 1 zuivelportie = 1 stevig glas melk 1 pot yoghurt 1 schel kaas

n e . r h . P s u e G ANTIRESORPTIEVE MEDICATIES

n e Selected bisphosphonate-associated adverse events of interest . r h . P s u e G Liwiecki, Drugs 2011; 71 (6): 791

n e . r h . P s u e G BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAW (ONJ, BONJ, BRONJ)

n e Risk factors for bisphosphonate-associated osteonecrosis of the jaw . r h . P s u e G Khosla, J Bone Miner Res, 2007, 1479

n e Differential diagnosis of osteonecrosis of the jaw in bisphosphonate-treated patients . r h . P s u e G Khosla, J Bone Miner Res, 2007, 1479

ONJ in cancer patients n e s u e G • The incidence of bisphosphonate-associated ONJ is highest in patients with underlying malignancies • who receive high doses of iv bisphosphonates (e.g. zoledronic acid, 4mg iv every 3–4 wk) to decrease the risk of skeletal complications of malignancy • 1 and 10% may go on to develop ONJ . r h . P Khosla, JCEM, 2012

Association between exposure to oral BPs and ONJ in osteoporosis . r h . P n e s u e G Italian record linkage claims database with a target population of 6 million over 55 years of age Incidence rate: 36.6 per 100,000 person-years Lapi, Osteoporos Int (2013) 24:697

ONJ in osteoporosis . r h . P n e s u e G Solomon, Osteoporos Int (2013) 24:237

ONJ in osteoporosis . r h . P n e s u e G Solomon, Osteoporos Int (2013) 24:237

n e . r h . P s u e G ATYPICAL FEMUR FRACTURE

AFF . r h . P n e s u e G Ng & Png, JBMR, 2013, online

n e Definition of atypical femur fracture, requiring the presence of each of the listed major features s u e G Prodromes in >50% of cases Often bilateral . r h . P Shane, J Bone Miner Res 2010, 2267

n e Case reports in the literature and reports in the FAERS database of bisphosphonate-associated atypical femoral fractures from January 1996 to September 2011 . r h . P s u e G Edwards, Bone Joint Surg Am. 2013;95:297-307

n e . r h . P s u e G Edwards, Bone Joint Surg Am. 2013;95:297-307

n e The risk of subtrochanteric and femoral shaft fractures in bisphosphonate users from large observational studies . r h . P s u e G Saleh, Orthop Clin N Am 44 (2013) 137–151

n e . r h . P s u e G Prasarn, Clin Orthop Relat Res (2012) 470:2295–2301

n e Randomeffects analysis of the studies for the association between bisphosphonate use and subtrochanteric, femoral shaft, and atypical femur fracture (AFF), . r h . P s u e G Gedmintas, JBMR, 2013, 1729

n e Random effects analysis of the studies for the association between bisphosphonate use and subtrochanteric, femoral shaft, and atypical femur fracture (AFF), stratified by outcome definition . r h . P s u e G Gedmintas, JBMR, 2013, 1729

n e Random effects analysis of the studies for the association between long‐term bisphosphonate use (5 years or greater) and subtrochanteric and femoral shaft fractures . r h . P s u e G Gedmintas, JBMR, 2013, 1729

AFF Duration of BPs . r h . P n e s u e G Time to union Thompson, J Bone Joint Surg Br, 2012;94-B:385–90.

Bisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older Women s u e G * . r h ST/D FN/intertroch . P 42 817 n e * 349 5587 204 2438 * 121 881 Park, JAMA, February 23, 2011—Vol 305, No. 8 783

n e Bisphosphonate Use and Atypical Fractures of the Femoral Shaft (atypical subtrochanteric fractures, n=56) 80 70 60 50 40 30 20 . r h 10 0 0 Natyp 13 Nwomen 1437820 . P <1yr 3 15672 1--2yr 4 21406 s u e G >2yr 39 46233 HR N cases stop BPs <1yr 42 83311 1--2yr >2yr 1 3 70036 75583 Schilcher, N Engl J Med 2011;364:1728-37.

Bone microarchitecture in AFF . r h . P n e s u e G Zanchetta, JBMR, 2013, online

n e Microindentation values for the four groups of study subjects. (A) Total indentation distance (Total ID), age-adjusted statistical differences . r h . P s u e G Guerri, Journal of Bone and Mineral Research, Vol. 28, 2013, pp 162

n e Reduction in bone scan uptake post-teriparatide treatment. Bone scintigraphy scans pre- and post-teriparatide treatment showing reduction in the intensity of isotope uptake (n=4). . r h . P s u e G Chiang, Bone 52 (2013) 360–365

n e . r h . P s u e G BISFOSFONATEN EN SLOKDARM KANKER MUMC&UHasselt

n e . r h MUMC&UHasselt . P s u e G Dixon, Nat. Rev. Rheumatol. 2011, 369

n e . r h MUMC&UHasselt . P s u e G Dixon, Nat. Rev. Rheumatol. 2011, 369

n e . r h . P s u e G DENOSUMAB AND INFECTIONS

Serious adverse events of cellulitis and erysipelas and relationship to timing of administration . r h . P n e s u e G Watts, OI, 2012

Denosumab vs. Placebo Infections . r h . P n e s u e G Watts, OI, 2012

Denosumab 6 yrs . r h . P s u e G n e

n e . r h . P s u e G FRACTUURHELING

Fracture healing . r h . P n e s u e G Claes, NRR, 2012

Fracture healing • Bisphosphonates – Increased callus s u e G • Denosumab (Adami, JBJS, 2012) . P – No delayed union • Teriparatide . r h – Positive effect? n e • NSAIDs (Geusens, Curr Opin Rh, 2013) – Avoid long-term use after recent fracture

n e . r h . P s u e G ANABOLE MIDDELEN

Teriparatide s u e G n e • In clinical trials the following reactions were reported at a ≥ 1% difference in frequency from placebo: . P – vertigo, nausea, pain in limb, dizziness, depression, dyspnoea . r h

n e . r h . P s u e G STRONTIUM RANELAAT

Strontium ranelate s u e G n e • Drug rash with eosinophilia and systemic symptoms (DRESS) (Cacoub, OI, 2012) – 1/24.000 (France) • DVT (Osborne, Drug Saf 2010) . P – Incidence: 6/1000 patient yrs • CV events (EMEA 2013) . r h – Protelos/Osseor should not be used in patients with current or past history of ischaemic heart disease (such as angina or a heart attack), peripheral arterial disease (obstruction of large blood vessels, often in the legs) or cerebrovascular disease (diseases affecting the blood vessels supplying the brain, such as stroke). – Protelos/Osseor should not be used in patients with hypertension (high blood pressure) that is not adequately controlled by treatment.

n e Veiligheid s u e G • Bisfosfonaten (JCEM 2012:2272) – – – – Osteonecrose kaak Atypische femurfracturen Atriumfibrillatie Oesofagus carcinoom . P 0.001 – 0.1% 0,0005% - 0,2% associatie in één studie geen associatie • Denosumab (JCEM 2013:4483) . r h – Osteonecrose kaak – Atypische femurfracturen – Infecties / cellulitis 8 casus 2 casus 1,4 en <0,1%

63-year-old woman with: - rheumatoid arthritis for 30 years - diabetes for 3 years - alendronate 70mg weekly for 7 years . P 6 months . r h Baseline: Spinal compression fractures L3 and L4 T-score spine: -2.25 n e s u e G No mention of calcium and vitamin D intake or follow up strategy! J Clin Endocrinol Metab 98: E723–E726, 2013

Follow up tijdens behandeling: gestructureerde monitoring Sterk aanbevolen Kan zinvol zijn Start therapie n e s u e G Gestructureerde klinische monitoring (min. na 3 maanden, nadien jaarlijks) Intolerantie . r h Non Compliance Niet-wervel fractuur na 1 jaar therapie . P Botmarkers Zo nodig andere medicatie of SC of IV Klinisch vermoeden van nieuwe wervelfractuur Bij twijfel/vragen RX DXA na 2-3 jaar Overleg Teriparatide (2de keuze: PTH), na 3de fractuur waaronder 2 wervelfracturen

Conclusies n e s u e G • Gezien de zeer lage incidentie van ONJ en AFF versus de belangrijke fractuurreductie met bisfosfonaten en denosumab, is de risico/benefit verhouding duidelijk in het voordeel van behandeling van patiënten met een hoog fractuurrisico: . P – met een wervel of heupfractuur – of een BMD T-score <2.5 . r h • Of dit ook het geval is wanneer patiënten geselecteerd worden op basis van FRAX of Garvan, noodzaakt verder onderzoek

Add a comment

Related presentations

Related pages

Opo | LinkedIn

Seminiar 30-11-2013 Side effects treat opo short. 175 Views. opsodiili. Opo-päivät Oulu 2016. 48 Views. NrdNashville. Nrd denver final opo mop fy11. 370 ...
Read more

Seminiar 30-11-2013 Side effects treat opo short ...

Stichting IWO wil bijdragen aan projecten die tot doel hebben om osteoporose onder de aandacht te brengen van een groter medisch publiek.
Read more

Seminar 30-11-2013 SLE fractures - Health & Medicine

Seminiar 30-11-2013 Side effects treat opo short Side effects treat opo short Dainik VIJAY NEWS Year 9, Issue : 302 Date : 30/11/2013 Dainik ...
Read more

ReGen-X Short - Documents - Docslide.nl

Share ReGen-X Short. ... Seminiar 30-11-2013 Side effects treat opo short Side effects treat opo short
Read more

Improving high-power OPO performance - Laser Focus World

Improving high-power OPO performance. ... and directional effects, ... Side pumping of an OPO is not possible, ...
Read more

Brain, Workout, and Health Supplements | Onnit

This product is not intended to diagnose, treat, cure, or prevent any disease. ... Onnit™ prides itself on the verity of our endorsements.
Read more

Workshop hes ll14 - slidesearch.org

Het gebruik van bisfosfonaten is geen weldaad voor de kaak door drs. J. Hes
Read more

christine-f-wildsoet-od-phd - UC Berkeley School of Optometry

... Home Research NEI Summer Research Projects Faculty Christine F. Wildsoet, OD, PhD. ... Seminars, or Group Research. Director, ... (short-sightedness) ...
Read more